Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

Cancers

Antonino Grassadonia¹  Pasquale Cioffi³  Felice Simiele³  Laura Iezzi²  Marinella Zilli² 

[1] Department of Experimental and Clinical Sciences, University ’G. d’Annunzio’, I-66013 Chieti, Italy; E-Mail:;Oncology Department, “SS. Annunziata” Hospital, I-66013 Chieti, Italy; E-Mails:;Hospital Pharmacy, “SS. Annunziata” Hospital, I-66013 Chieti, Italy; E-Mails:

关键词: hydroxamate-based histone deacetylase inhibitors;    histone deacetylase inhibitors;    vorinostat;    belinostat;    panobinostat;    pracinostat;    abexinostat;    resminostat;   

DOI  :  10.3390/cancers5030919

来源: mdpi

【 摘 要 】

Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.